The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: A review

Canadian Journal of Psychiatry

Volumn 55, Issue 3, 2010, Pages 126-135

  Sinyor, Mark ^a   Schaffer, Ayal ^a,b   Levitt, Anthony ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

Adult; Antidepressant; Cognitive behavioural therapy; Depression; Pragmatic trial

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; FLUOXETINE; LIOTHYRONINE; LITHIUM; MIRTAZAPINE; NORTRIPTYLINE; PLACEBO; SERTRALINE; TRANYLCYPROMINE; VENLAFAXINE;

ALTERNATIVE MEDICINE; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; FOLLOW UP; GENERAL PRACTICE; HEALTH CARE COST; HUMAN; MAJOR DEPRESSION; MONOTHERAPY; PATIENT SATISFACTION; PRIMARY MEDICAL CARE; PROGNOSIS; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; SELF REPORT; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 77950385461     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371005500303     Document Type: Review

References (46)

1. Zimmerman M, Chelminski I, Posternak MA. Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry. 2005;162(7):1370-1372.
2. Rush AJ, Prien RF. From scientific knowledge to the clinical practice of psychopharmacology: can the gap be bridged? Psychopharmacol Bull. 1995;31(1):7-20.
3. Khan A, Schwartz K. Study designs and outcomes in antidepressant clinical trials. Essent Psychopharmacol. 2005;6(4):221-226.
4. Posternak MA, Zimmerman M, Keitner GI, et al. A reevaluation of the exclusion criteria used in antidepressant efficacy trials. Am J Psychiatry. 2002;159:191-200.
5. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
6. Lavori PW, Rush AJ, Wisniewski SR, et al. Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry. 2001;50(10):792-801.
7. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;18;289(23):3095-3105.
8. Trivedi MH, Rush AJ, Gaynes BN, et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care. Neuropsychopharmacology. 2007;32(12):2479-2489.
9. Gaynes BN, Rush AJ, Trivedi MH, et al. Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. J Gen Intern Med. 2008;23(5):551-560.
10. Thase ME. Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry. 2003;13(Suppl 64):18-25.
11. Judd LL. Major depressive disorder: longitudinal symptomatic structure, relapse and recovery. Acta Psychiatr Scand. 2001;104(2):81-83.
12. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999;60(4):221-225.
13. Paykel ES. Remission and residual symptomatology in major depression. Psychopathology. 1998;31(1):5-14.
14. Rafanelli C, Fava GA, Sonino N. Sequential treatment of depression in primary care. Int J Clin Pract. 2007;61(10):1719-1729.
15. Fava GA, Ruini C, Rafanelli C. Sequential treatment of mood and anxiety disorders. J Clin Psychiatry. 2005;66(11):1392-1400.
16. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119-142.
17. Zimmerman M, Posternak MA, Chelminski I. Symptom severity and exclusion from antidepressant efficacy trials. J Clin Psychopharmacol. 2002;22(6):610-614.
18. Zimmerman M, Chelminski I, Posternak MA. Exclusion criteria used in antidepressant efficacy trials: consistency across studies and representativeness of samples included. J Nerv Ment Dis. 2004;192(2):87-94.
19. Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the quick inventory of depressive symptomatology and the Hamilton Rating Scale for Depression: a Sequenced Treatment Alternatives to Relieve Depression trial report. Biol Psychiatry. 2006;59(6):493-501.
20. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry. 2007;164(5):739-752.
21. Wisniewski SR, Eng H, Meloro L, et al. Web-based communications and management of a multi-center clinical trial: the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project. Clin Trials. 2004;1(4):387-398.
22. Shaw BF. Specification of the training and evaluation of cognitive therapists for outcome studies, in psychotherapy research: where we are and where we should go. Williams JBW, Spitzer RL, editors. New York (NY): Guilford Press; 1984. p 173-189.
23. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1519-1530.
24. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006;163(7):1161-1172.
25. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1531-1541.
26. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
27. National Institute of Mental Health [website]. Questions and answers about the NIMH Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study - background [Internet]. Bethesda (MD): NIMH Press Office; 2006 [cited 2008 Aug 29]. Available from: http://www.nimh.nih.gov/health/trials/ practical/stard/questions-and-answers-about-the-nimh-sequenced-treatment- alternatives-to-relieve-depression-stard-study-background.shtml.
28. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231-1242.
29. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243-1252.
30. Warden D, Rush AJ, Trivedi MH, et al. The STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007;9(6):449-459.
31. Sinyor M, Levitt AJ, Cheung AH, et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? J Clin Psych. Forthcoming.
32. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165(3):342-351.
33. Rush AJ. STAR*D: what have we learned? Am J Psychiatry. 2007;164(2):201-204.
34. Zimmerman M, Posternak M, Friedman M, et al. Which factors influence psychiatrists' selection of antidepressants? Am J Psychiatry. 2004;161(7):1285-1289.
35. Gaynes BN, Rush AJ, Trivedi M, et al. A direct comparison of presenting characteristics of depressed outpatients from primary vs specialty care settings: preliminary findings from the STAR*D clinical trial. Gen Hosp Psychiatry. 2005;27(2):87-96.
36. Huynh NN, McIntyre RS. What are the implications of the STAR*D trial for primary care? A review and synthesis. Prim Care Companion J Clin Psychiatry. 2008;10(2):91-96.
37. Quitkin FM, Petkova E, McGrath PJ, et al. When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry. 2003;160(4):734-740.
38. Warden D, Trivedi MH, Wisniewski SR, et al. Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry. 2007;164(8):1189-1197.
39. Nemeroff CB, Entsuah R, Benattia I, et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry. 2008;63(4):424-434.
40. Thase ME, Friedman ES, Berman SR, et al. Is cognitive behavior therapy just a 'nonspecific' intervention for depression? A retrospective comparison of consecutive cohorts treated with cognitive behavior therapy or supportive counseling and pill placebo. J Affect Disord. 2000;57(1-3):63-71.
41. Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000;342(20):1462-1470. Erratum in: N Engl J Med. 2001;345(3):232.
42. Hollon SD, DeRubeis RJ, Shelton RC, et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry. 2005;62(4):417-422.
43. Myhr G, Payne K. Cost-effectiveness of cognitive-behavioural therapy for mental disorders: implications for public health care funding policy in Canada. Can J Psychiatry. 2006;51(10):662-670.
44. Shaw BF, Elkin I, Yamaguchi J, et al. Therapist competence ratings in relation to clinical outcome in cognitive therapy of depression. J Consult Clin Psychol. 1999;67(6):837-846.
45. DeRubeis RJ, Hollon SD, Amsterdam JD, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry. 2005;62(4):409-416.
46. Jacobson NS, Hollon SD. Cognitive-behavior therapy versus pharmacotherapy: now that the jury's returned its verdict, it's time to present the rest of the evidence. J Consult Clin Psychol. 1996;64(1):74-80.